 "Novartis India Q2 net rises multi-fold to Rs 104 crore")
The company had posted a net profit of Rs 14 crore a year ago.
"The company has received a sale consideration in relation to the slump sale of the OTC division to GSK CPL amounting to Rs 1,097.3 million and the same has been accounted for in the quarter ended September 30, 2015 results," Novartis said in a note.
Also Read
The company's board in January had approved a slump sale of OTC business to GSK Consumer Private Limited.
In April, Novartis had agreed to divest its global Animal Health business to Lilly by transferring it to Elanco India or another affiliate of Lilly.
"The sale consideration for the slump sale of the animal health division to Elanco India amounting to Rs 866.8 million has not been accounted for in the quarter ended September 30, 2015 results because this transaction is subject to the receipt of all applicable legal and regulatory approvals," Novartis said in a statement.
Novartis showed the net profit from the sale of the OTC division and costs incurred by the company in relation to these transactions under extraordinary items.
The stand-alone total income from operations of the company declined 4.4% to Rs 224.43 crore during the reported quarter, from Rs 234.79 crore in the year-ago period.
The stock was trading at Rs 887.75, up 3.11% on BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%